1. Targeting APRIL in the treatment of glomerular diseases.
- Author
-
Cheung CK, Barratt J, Lafayette R, Liew A, Suzuki Y, Tesař V, Trimarchi H, Wong MG, Zhang H, and Rizk DV
- Subjects
- Humans, Animals, Kidney Glomerulus immunology, Kidney Glomerulus pathology, Kidney Glomerulus drug effects, Tumor Necrosis Factor Ligand Superfamily Member 13 antagonists & inhibitors, Tumor Necrosis Factor Ligand Superfamily Member 13 immunology, B-Lymphocytes immunology, B-Lymphocytes drug effects, Glomerulonephritis, IGA immunology, Glomerulonephritis, IGA drug therapy
- Abstract
A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell-depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage., (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF